Revenio Group Oyj

Ticker/ISIN
REG1V
FI0009010912
Marknad/Land
Main Market, Helsinki
Sweden

Om Revenio Group Oyj

Revenio Group is a Nordic provider of solutions for automated materials handling and for technical information solutions, translation and localization services, multilingual documentation, and tonometers. The Group consists of the independent subsidiaries:* Revenio Group Information Oy - provides translation and localization services as well as multilingual documentation services.* Revenio Group Logistics Oy - streamlines material and information flows by providing customers with automated materials handling systems and the supporting information systems. * Tiolat Oy - specializes in instruments for investigating Intra Ocular Pressure (IOP), including iCare-tonometers, to eye specialists and opticians.

Senaste sammanfattade pressmeddelande från Revenio Group Oyj

Revenio Group Corporation announced that it will release its financial statement for 2024 on February 13, 2025, at approximately 09:00 a.m. EET. The release will be accessible on their website. A live webcast and teleconference for analysts, investors, and media will take place at 3:30 p.m. EET on the same day, with presentations by CEO Jouni Toijala and CFO Robin Pulkkinen. The webcast can be viewed online, and participants attending in person must register by February 11, 2025. A recording of the webcast will be available on the company's website after the event. Revenio Group is a global provider of ophthalmic diagnostic solutions, with 2023 net sales of EUR 96.6 million and an operating profit of EUR 26.3 million. The company is listed on Nasdaq Helsinki.
Revenio Group Corporation announced updates regarding the release of the new version of the iCare MAIA® microperimeter, developed by its subsidiary, iCare. The updated microperimeter retains key features and introduces improvements like a renewed hardware platform, fully automated operations, a 15-inch multi-touch display, and a 60° TrueColor field of view for enhanced structure-function correlation. The commercial launch is scheduled for the first quarter of next year, aligning with Revenio's growth and innovation strategy to meet market demands, particularly in ophthalmic research focused on geographic atrophy therapies. The new device offers full interchangeability with previous models and includes features like an intuitive user interface and customizable test patterns. Revenio Group is a global provider of eye care diagnostic solutions, with iCare specializing in innovative diagnostic tools for eye diseases. Revenio's net sales in 2023 were EUR 96.6 million, with an operating profit of EUR 26.3 million.
Revenio Group Corporation announced its schedule for financial reports in 2025, with the financial statements bulletin, half-year report, and interim reports to be released around 9:00 am Finnish time on specified dates. The Annual General Meeting is set for April 10, 2025, with requests to include agenda items due by February 21, 2025. Revenio, a global provider of eye care diagnostic solutions, reported net sales of EUR 96.6 million and an operating profit of EUR 26.3 million in 2023. The company is listed on Nasdaq Helsinki under the trading code REG1V. For more information, contact CFO Robin Pulkkinen.
Revenio Group Corporation reported strong organic growth in the third quarter of 2024, with exchange rate-adjusted net sales increasing 6.2 percentage points faster than reported growth. Despite exchange rate challenges, sales grew across key markets, notably in the US and APAC regions. The company highlighted significant growth in sales of tonometers and fundus imaging devices, with new products like the iCare ST500 and iCare EIDON AF receiving positive market reception and regulatory approvals. Revenio's acquisition of Thirona Retina supports its strategy to enhance eye diagnostics through AI-based solutions. The company continues to focus on its growth strategy for 2024–2026, despite geopolitical risks and limited future visibility. Revenio's financial performance remains strong, with continued investment in innovative eye care solutions.
Revenio Group Corporation announced that its interim report for January-September 2024 will be released on October 31, 2024, at approximately 09:00 a.m. (EET). The report will be accessible on their website. An audiocast and teleconference for analysts and investors will take place at 3:00 p.m. (EET) on the same day, with details for joining provided through registration links. A recording of the audiocast will be available online after the event. Revenio Group is a global provider of eye care diagnostic solutions, offering tools for diagnosing conditions like glaucoma and diabetic retinopathy. In 2023, the company reported net sales of EUR 96.6 million and an operating profit of EUR 26.3 million. Revenio is listed on Nasdaq Helsinki. For more details, contact CFO Robin Pulkkinen.
Revenio Group Corporation announced the launch of the iCare ST500™, a new slit lamp-based tonometer developed by its subsidiary, iCare. The device integrates iCare's rebound tonometry technology into a modern slit lamp design, offering ease of use for practitioners and comfort for patients. Clinical validation shows that the iCare ST500™ provides intraocular pressure (IOP) measurements comparable to the gold standard applanation tonometry, with less variability between repeated tests. The device also features a new SmartCradle for improved connectivity and a rechargeable lithium battery. The iCare ST500™ aims to enhance clinical workflow efficiency and accuracy in IOP measurements. Revenio Group is a global provider of eye care diagnostic solutions, including tonometers and fundus imaging devices, with significant sales and operating profit in 2023. iCare specializes in innovative eye disease diagnostic tools and is part of the Revenio Group, listed on Nasdaq Helsinki.
Revenio Group Corporation announced that its subsidiary, Icare Finland Oy, has acquired Thirona Retina B.V., an AI software company, from Thirona B.V. Icare initially invested EUR 1.9 million in Thirona Retina in 2023 and has now purchased the remaining shares for approximately EUR 4.8 million. This acquisition aligns with Revenio’s strategy to enhance ophthalmic diagnostics through innovative solutions. Thirona Retina’s AI product, RetCAD™, is used for screening eye diseases like diabetic retinopathy and glaucoma. The integration of Thirona Retina is expected to bolster Revenio’s AI-based ophthalmic solutions, improving eye care diagnostics and access globally. Thirona Retina will continue to sell its RetCAD™ solution to other industry vendors and maintain existing collaborations.
Revenio Group Corporation released a stock exchange notification on August 14, 2024, stating that senior manager Kate Taylor received a share-based incentive on August 13, 2024. The transaction involved 333 shares at a unit price of 0 EUR. Revenio Group is a global provider of eye care diagnostic solutions, including devices for diagnosing glaucoma, diabetic retinopathy, and macular degeneration. In 2023, Revenio's net sales were EUR 96.6 million, with an operating profit of EUR 26.3 million. The company is listed on Nasdaq Helsinki under the trading code REG1V. For more information, contact CFO Robin Pulkkinen.

Threads

Main Market, Helsinki News profile image

Main Market, Helsinki News

Nyhetsuppdatering från Revenio Group Oyj

Förändringar i återköpta aktier: Revenio Group Corporation to transfer shares related to the Oculo share-based incentive scheme for 2021-2023

Revenio Group Corporation's Board of Directors has decided to issue shares in a directed share issue without payment, based on authorization from the Annual General Meeting on April 4, 2024. The shares will be given to key persons of the subsidiary Icare World Australia Pty Ltd. (formerly Oculo) as part of a long-term incentive and commitment program. This program, covering the years 2021-2023, aims to align the interests of shareholders and participants, support the company's strategy, and enhance long-term value and performance. A maximum of AUD 1,660,000 worth of shares was allocated, calculated at the trading-weighted average price on April 27, 2021. A total of 833 treasury shares will be transferred, leaving the company with 84,309 treasury shares. For more information, contact CFO Robin Pulkkinen. Revenio Group provides eye care diagnostic solutions and reported net sales of EUR 96.6 million and an operating profit of EUR 26.3 million in 2023. The company is listed on Nasdaq Helsinki with the trading code REG1V.

1. Bifogad dokument

Main Market, Helsinki News profile image

Main Market, Helsinki News

Nyhetsuppdatering från Revenio Group Oyj

Transaktioner utförda av personer i ledande ställning: Revenio Group Corporation: Managers' Transactions - Bill Östman

Revenio Group Corporation has issued an initial notification about a share-based incentive received by Bill Östman, a member of the board. The transaction involved 719 shares at a unit price of 0 EUR. Revenio Group is a global provider of eye care diagnostic solutions and is listed on Nasdaq Helsinki. In 2023, the company reported net sales of EUR 96.6 million and an operating profit of EUR 26.3 million.

1. Bifogad dokument

Main Market, Helsinki News profile image

Main Market, Helsinki News

Nyhetsuppdatering från Revenio Group Oyj

Transaktioner utförda av personer i ledande ställning: Revenio Group Corporation: Managers' Transactions - Riad Sherif

Revenio Group Corporation has released a stock exchange notification concerning a share-based incentive received by Riad Sherif, a board member. The transaction took place outside a trading venue on May 7, 2024, and involved 457 shares at a unit price of 0 EUR. The notification is the initial one, with a reference number of 61954/4/4. Revenio Group, a global provider of eye care diagnostic solutions, recorded a net sales of EUR 96.6 million and an operating profit of EUR 26.3 million in 2023. The company is listed on Nasdaq Helsinki under the trading code REG1V.

1. Bifogad dokument

Main Market, Helsinki News profile image

Main Market, Helsinki News

Nyhetsuppdatering från Revenio Group Oyj

Transaktioner utförda av personer i ledande ställning: Revenio Group Corporation: Managers' Transactions - Pekka Tammela

Revenio Group Corporation has announced that Pekka Tammela, a member of the board, has received a share-based incentive. The transaction, which occurred outside a trading venue, involved 653 shares at a unit price of 0 EUR. The announcement was made in an initial notification, with a reference number of 61939/4/4. Further information can be obtained from CFO Robin Pulkkinen. Revenio Group Corporation is a provider of eye care diagnostic solutions and is listed on Nasdaq Helsinki. In 2023, the company's net sales were EUR 96.6 million, with an operating profit of EUR 26.3 million.

1. Bifogad dokument

Main Market, Helsinki News profile image

Main Market, Helsinki News

Nyhetsuppdatering från Revenio Group Oyj

Transaktioner utförda av personer i ledande ställning: Revenio Group Corporation: Managers' Transactions - Ann-Christine Sundell

Revenio Group Corporation has issued an initial notification that Ann-Christine Sundell, a member of the board, has received a share-based incentive. The transaction, which occurred outside a trading venue, involved 457 shares at a unit price of 0 EUR. The company, a global provider of eye care diagnostic solutions, reported net sales of EUR 96.6 million and an operating profit of EUR 26.3 million in 2023. Revenio Group Corporation is listed on Nasdaq Helsinki under the trading code REG1V.

1. Bifogad dokument

Main Market, Helsinki News profile image

Main Market, Helsinki News

Nyhetsuppdatering från Revenio Group Oyj

Förändringar i återköpta aktier: Revenio Group Corporation: Transfer of the Company's own shares

Revenio Group Corporation has transferred 3,200 treasury shares to its Board of Directors as part of their annual remuneration. This decision, made during the AGM on April 4, 2024, allows for around 40% of the Board's annual remuneration to be paid in company shares, with the remaining 60% being a monetary payment from which tax will be deducted. The share payment is valued using the weighted average value of the share on the day after the release of the Q1 2024 Interim Report. Following this transfer, Revenio now holds 85,142 of its treasury shares. The company's CFO, Robin Pulkkinen, is available for further information.

1. Bifogad dokument

Main Market, Helsinki News profile image

Main Market, Helsinki News

Nyhetsuppdatering från Revenio Group Oyj

Transaktioner utförda av personer i ledande ställning: Revenio Group Corporation: Managers' Transactions - Arne Boye Nielsen

Revenio Group Corporation has announced that Arne Boye Nielsen, a member of the board, has received a share-based incentive. The transaction, which took place outside a trading venue, involved 914 shares at a unit price of 0 EUR. This is an initial notification, with the reference number 61945/4/4. The company is a global provider of eye care diagnostic solutions, with net sales in 2023 totaling EUR 96.6 million and an operating profit of EUR 26.3 million.

1. Bifogad dokument